Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing
Urology Times News Network: LUGPA 2025
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.
Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”
Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.
Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.
Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
